Elizabeth H. Golembiewski, Andrea E. Garcia Bautista, Eric C Polley, Guillermo E Umpierrez, Rodolfo J. Galindo, Juan P. Brito, Victor M. Montori, Janet P. Gockerman, Michael Tesulov, Bertina Labatte, Mindy M. Mickelson, Rozalina G. McCoy
{"title":"患者在选择降糖药物时看重的症状和属性:混合方法研究","authors":"Elizabeth H. Golembiewski, Andrea E. Garcia Bautista, Eric C Polley, Guillermo E Umpierrez, Rodolfo J. Galindo, Juan P. Brito, Victor M. Montori, Janet P. Gockerman, Michael Tesulov, Bertina Labatte, Mindy M. Mickelson, Rozalina G. McCoy","doi":"10.2337/cd23-0042","DOIUrl":null,"url":null,"abstract":"This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).","PeriodicalId":504780,"journal":{"name":"Clinical Diabetes","volume":"5 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Outomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study\",\"authors\":\"Elizabeth H. Golembiewski, Andrea E. Garcia Bautista, Eric C Polley, Guillermo E Umpierrez, Rodolfo J. Galindo, Juan P. Brito, Victor M. Montori, Janet P. Gockerman, Michael Tesulov, Bertina Labatte, Mindy M. Mickelson, Rozalina G. McCoy\",\"doi\":\"10.2337/cd23-0042\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).\",\"PeriodicalId\":504780,\"journal\":{\"name\":\"Clinical Diabetes\",\"volume\":\"5 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Diabetes\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2337/cd23-0042\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Diabetes","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2337/cd23-0042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Outomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study
This mixed-methods study sought to identify pharmacotherapy preferences among 40 noninsulin-treated adults with type 2 diabetes receiving care at two U.S. health care systems. Participants ranked by relative importance various health outcomes and medication attributes and then contextualized their rankings. Most participants ranked blindness (63%), death (60%), heart attack (48%), and heart failure (48%) as the most important health outcomes and glucose-lowering efficacy (68%) as the most important medication attribute, followed by oral administration (45%) and lack of gastrointestinal side effects (38%).